Literature DB >> 31401364

Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Andrew M Moon1, Amit G Singal2, Elliot B Tapper3.   

Abstract

BACKGROUND & AIMS: Accurate estimates for the contemporary burden of chronic liver disease (CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the incidence, prevalence, and mortality of CLD and its resulting complications, including cirrhosis and hepatocellular carcinoma (HCC).
METHODS: We reviewed the published literature on the incidence, prevalence, trends of various etiologies of CLD and its resulting complications. In addition, we provided updated data from the Centers for Disease Control and Global Burden of Disease Study on the morbidity and mortality of CLD, cirrhosis, and hepatocellular carcinoma (HCC). Lastly, we assessed the strengths and weaknesses of available sources of data in hopes of providing important context to these national estimates of cirrhosis burden.
RESULTS: An estimated 1.5 billion persons have CLD worldwide and the age-standardized incidence of CLD and cirrhosis is 20.7/100,000, a 13% increase since 2000. Similarly, cirrhosis prevalence and mortality has increased in recent years in the United States. The epidemiology of CLD is shifting, reflecting implementation of large-scale hepatitis B vaccination and hepatitis C treatment programs, the increasing prevalence of the metabolic syndrome, and increasing alcohol misuse.
CONCLUSIONS: The global burden of CLD and cirrhosis is substantial. Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the CLD burden in some parts of the world, concomitant increases in injection drug use, alcohol misuse, and metabolic syndrome threaten these trends. Ongoing efforts to address CLD-related morbidity and mortality require accurate contemporary estimates of epidemiology and outcomes.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol-related; Hepatitis B; Hepatitis C; Liver Cancer; Nonalcoholic Fatty Liver Disease

Year:  2019        PMID: 31401364      PMCID: PMC7007353          DOI: 10.1016/j.cgh.2019.07.060

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  150 in total

1.  Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study.

Authors:  Jennifer C Lai; Jennifer L Dodge; Saunak Sen; Kenneth Covinsky; Sandy Feng
Journal:  Hepatology       Date:  2015-12-16       Impact factor: 17.425

Review 2.  Patient-reported outcomes in cirrhosis: A scoping review of the literature.

Authors:  Elliot B Tapper; Fasiha Kanwal; Sumeet K Asrani; Chanda Ho; Nadia Ovchinsky; John Poterucha; Avegail Flores; Judith E Smith; Victor Ankoma-Sey; Bruce Luxon; Michael L Volk
Journal:  Hepatology       Date:  2018-04-19       Impact factor: 17.425

3.  Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden.

Authors:  Björn Lindkvist; Maria Benito de Valle; Bo Gullberg; Einar Björnsson
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

Review 4.  Alcoholic liver disease: pathogenesis and new therapeutic targets.

Authors:  Bin Gao; Ramon Bataller
Journal:  Gastroenterology       Date:  2011-09-12       Impact factor: 22.682

5.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

Authors:  Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo
Journal:  Gastroenterology       Date:  2013-03-06       Impact factor: 22.682

Review 6.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Authors:  Aparna Schweitzer; Johannes Horn; Rafael T Mikolajczyk; Gérard Krause; Jördis J Ott
Journal:  Lancet       Date:  2015-07-28       Impact factor: 79.321

7.  Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015.

Authors:  Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-27       Impact factor: 4.254

Review 8.  Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.

Authors:  Robert S Brown; Brian J McMahon; Anna S F Lok; John B Wong; Ahmed T Ahmed; Mohamed A Mouchli; Zhen Wang; Larry J Prokop; Mohammad Hassan Murad; Khaled Mohammed
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

9.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

10.  Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016.

Authors:  Yvan Hutin; Muazzam Nasrullah; Philippa Easterbrook; Boniface Dongmo Nguimfack; Esteban Burrone; Francisco Averhoff; Marc Bulterys
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-07-20       Impact factor: 17.586

View more
  130 in total

1.  Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.

Authors:  Elliot B Tapper; Devin Aberasturi; Zhe Zhao; Chia-Yang Hsu; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2020-05-03       Impact factor: 8.171

2.  Usefulness of Mac-2 binding protein glycosylation isomer in non-invasive probing liver disease in the Vietnamese population.

Authors:  Thuy Thi Thu Pham; Dat Tan Ho; Toan Nguyen
Journal:  World J Hepatol       Date:  2020-05-27

3.  Gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase can predict progression in patients with liver cirrhosis.

Authors:  Chenxi Liu; Yan Sun; Yao Yang; Yuemin Feng; Xiaoyu Xie; Lingyu Qi; Keke Liu; Ximing Wang; Qiang Zhu; Xinya Zhao
Journal:  Eur Radiol       Date:  2021-02-03       Impact factor: 5.315

4.  Harms of hepatocellular carcinoma surveillance.

Authors:  Jan Petrasek; Amit G Singal; Nicole E Rich
Journal:  Curr Hepatol Rep       Date:  2019-10-15

5.  Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.

Authors:  Jeff Y Yang; Andrew M Moon; Hannah Kim; Virginia Pate; A Sidney Barritt; Matthew J Crowley; John B Buse; Til Stürmer; Anastasia-Stefania Alexopoulos
Journal:  J Diabetes Complications       Date:  2020-08-05       Impact factor: 2.852

6.  Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries.

Authors:  Nadim Mahmud; David E Kaplan; Tamar H Taddei; David S Goldberg
Journal:  Liver Transpl       Date:  2021-02-15       Impact factor: 5.799

7.  The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.

Authors:  Huikuan Chu; Lu Jiang; Bei Gao; Nagsen Gautam; Jawaher A Alamoudi; Sonja Lang; Yanhan Wang; Yi Duan; Yazen Alnouti; Edward E Cable; Bernd Schnabl
Journal:  Transl Res       Date:  2020-06-15       Impact factor: 7.012

8.  Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population.

Authors:  Mariana Lazo; Usama Bilal; Mack C Mitchell; James Potter; Ruben Hernaez; Jeanne M Clark
Journal:  Clin Gastroenterol Hepatol       Date:  2020-08-31       Impact factor: 11.382

9.  Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis.

Authors:  Nadim Mahmud; Zachary Fricker; Rebecca A Hubbard; George N Ioannou; James D Lewis; Tamar H Taddei; Kenneth D Rothstein; Marina Serper; David S Goldberg; David E Kaplan
Journal:  Hepatology       Date:  2020-12-10       Impact factor: 17.425

10.  Patient-Reported Barriers Are Associated With Receipt of Hepatocellular Carcinoma Surveillance in a Multicenter Cohort of Patients With Cirrhosis.

Authors:  Amit G Singal; Jasmin A Tiro; Caitlin C Murphy; James-Michael Blackwell; Jennifer R Kramer; Aisha Khan; Yan Liu; Song Zhang; Jessica L Phillips; Ruben Hernaez
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-03       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.